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Glucocorticoids (GC) are the most commonly prescribed medications for patients with
inflammatory diseases, despite their well-known adverse metabolic effects. Previously, it
was understood that the anti-inflammatory effects of the GC/GC receptor (GR) complex
were mediated via transrepression, whilst the adverse metabolic effects were mediated
via transactivation. It has recently become clear that this “divergent actions” paradigm
of GC actions is likely insufficient. It has been reported that the GC/GR-mediated
transactivation also contributes to the anti-inflammatory actions of GC, via up-regulation
of key anti-inflammatory proteins. One of these is glucocorticoid-induced leucine zipper
(GILZ), which inhibits inflammatory responses in a number of important immune cell
lineages in vitro, as well as in animal models of inflammatory diseases in vivo. This review
aims to compare the GILZ and GC effects on specific cell lineages and animal models of
inflammatory diseases. The fact that the actions of GILZ permit a GILZ-based gene therapy
to lack GC-like adverse effects presents the potential for development of new strategies
to treat patients with inflammatory diseases.
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INTRODUCTION
Glucocorticoids (GC) remain the most common prescription
to treat patients with immune-mediated inflammatory diseases,
despite their well-known side effects. The efficacy of GCs is under-
pinned by GC effects on intracellular pathways mediated via
forming a complex with the glucocorticoid receptor (GR). The
effects of the GC/GR complex depend on a combination of several
effects. These include (i) transrepression, whereby the GC-GR
complex tethers to pro-inflammatory transcription factors such
as NF-κB and AP-1, constraining their activity; (ii) cis-repression,
whereby the GC-GR complex binds directly to DNA and exerts
inhibitory effects on gene transcription; and (iii) transactivation,
whereby a GC-GR dimer acts as a bona fides transcription factor
and activates gene transcription (McKay and Cidlowski, 1999; De
Bosscher et al., 2003; Barnes, 2006; Beaulieu and Morand, 2011).
Despite their beneficial effects, adverse effects of GC treatment
have been noted since the beginning of their usage, because the
amount of GCs required therapeutically to inhibit the immune
system is in excess of metabolic homeostatic requirements. Until
lately, it was believed that GC/GR mediated transrepression was
predominantly responsible for the immune suppressive func-
tion of GCs, while GC/GR induced transactivation was linked
to GC adverse metabolic effects (Reichardt et al., 2001; Schacke
et al., 2005, 2007). Recently, however, a new role of GC/GR
transactivation in immune suppressive actions has emerged, due
to the functional characterization of several GC induced anti-
inflammatory proteins. Many studies have shown that one such
protein, glucocorticoid-induced leucine zipper (GILZ), inhibits
activation of a wide range of immune cells under inflamed condi-
tions (Beaulieu and Morand, 2011; Esposito et al., 2012; Cheng
et al., 2013; Ngo et al., 2013a). Importantly, published data to
date have not indicated GC-like adverse effects associated with
GILZ, suggesting that GILZ exerts immunosuppressive effects
that mimic those of GCs but occur via distinct pathways. In this
review, we aim to summarize current knowledge of GILZ biolog-
ical functions and compare them with the known effects of GC
on immune system. The similarities and divergence between the
effects of GILZ and GC suggest the potential use of GILZ-based
therapies in improving GC efficacy while reducing GC metabolic
toxicity, and thus the development of new treatment strategies to
replace supplement or even replace GC.
GLUCOCORTICOIDS AND GLUCOCORTICOID RECEPTORS
Inflammation is a self-protective process that forms part of the
host organism responses to harmful insults, such as cell dam-
age, foreign pathogens or irritants. To avoid excessive damage
to the healthy tissues, the activated immune system needs to
be rapidly “switched off” once the noxious stimuli are elimi-
nated. Therefore, inflammatory responses are tightly regulated
via competition between stimulative and suppressive signals. GC,
produced by the adrenal gland, represents one of the most pow-
erful endogenous pathways to temper the intensity of immune
responses. Under certain conditions, however, the ability of
endogenous GC to suppress immune response is overwhelmed,
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resulting in the hyper-activation of the immune system that
leads to chronic auto-immune and inflammatory disease. In the
majority of these diseases, treatment with synthetic GCs is used
to control inflammation, exploiting the natural pathways that
evolved to permit endogenous GC to regulate immune responses.
The profound effectiveness of GCs underpins their use in a wide
range of diseases. Despite their effectiveness, however, the use of
GCs is accompanied by a litany of serious adverse effects, particu-
larly in patients under long term or high dose treatment. These
unwanted effects include diabetes, immunosuppression, osteo-
porosis and increased risk of cardiovascular events, all of which
are closely associated with the physiological metabolic functions
of GC (Rhen and Cidlowski, 2005). The continued use of gluco-
corticoids reflects a failure to discover a reliable GC replacement.
To develop such glucocorticoid mimics, a large body of research
has been conducted to understand the molecular actions of GC.
MOLECULAR MECHANISMS OF GLUCOCORTICOID ACTIONS
GCs impact on intracellular pathways through binding to the GR
(Rhen and Cidlowski, 2005). The GC/GR complex exerts its tran-
srepression effects by tethering to and interfering with the func-
tion of proinflammatory transcription factors, such as NF-κB and
AP-1, which consequently results in repression of a large number
of proinflammatory mediators, cytokines, chemokines and adhe-
sion molecules (Rhen and Cidlowski, 2005; Nixon et al., 2013).
The GC/GR complex also suppresses gene expression via bind-
ing to negative GC response elements (nGRE) located within the
promoters of genes, a phenomena called cis-repression (Newton,
2000; Clark and Belvisi, 2012; Nixon et al., 2013; Vandevyver et al.,
2013). These GC/GR-induced transrepression and cis-repression
effects are important in the therapeutic activity of GCs. On the
other hand, the dimerized GC/GR complex is also capable of
binding to positive GREs and thereby up-regulating the expres-
sion of multiple genes, many of which are related to the metabolic
adverse effects of GCs (Rhen and Cidlowski, 2005; Clark and
Belvisi, 2012; Nixon et al., 2013; Vandevyver et al., 2013). It has
previously been believed that anti-inflammatory effects of GCs
are mediated via transrepression, whereas the metabolic effects
are mediated via transactivation (Figure 1A). Thus, a significant
effort has been invested by pharmaceutical companies world-
wide toward the discovery of “selective glucocorticoid receptor
modulators” (SGRM), based on the idea that GR ligands that
favor transrepression over transactivation would be equally effec-
tive but safer (Figure 1B) (Weinstein et al., 2011). As we have
recently reviewed, however, it has become clear that the “diver-
gent actions” paradigm of GC actions does not fully explain
the parallel therapeutic and metabolic effects of GCs (Fan and
Morand, 2012). For examples, nGREs were recently identified
within the promoters of a large number of genes, including
insulin, osteoprotegerin and anti-apoptotic proteins (Surjit et al.,
2011). GC/GR binding to these nGREs results in down-regulation
of gene expression, directly contributing to GC adverse metabolic
effects. Moreover, GC/GR-dimer induced transactivation effects
include the induction of the expression of several important anti-
inflammatory proteins, including GILZ, annexin A1 (AnxA1)
and MAPK phosphatase-1 (MKP-1) (Clark, 2003; Perretti and
D’Acquisto, 2009; Beaulieu and Morand, 2011; Clark and Belvisi,
2012; Ratman et al., 2013; Yang et al., 2013). Indeed, two recent
studies indicate that GC-GR-dimer-dependent effects, likely due
to transactivation of anti-inflammatory proteins, are essential
for the full anti-inflammatory effects of GCs (Baschant et al.,
2011; Kleiman et al., 2012). These findings demonstrate a pre-
viously under-recognized role of GC-induced proteins in the
anti-inflammatory effects of GC, suggesting that the paradigm
separating GC anti-inflammatory and metabolic effects on the
basis of transrepression and transactivation is inadequate to
explain the effects of GC.
To develop a new strategy to mimic GC immune-suppressive
functions but limit the metabolic effects, an alternate approach
would be to discover GC-mediated inhibitory effects on the
immune system that bypass the mechanism of GC metabolic
effects, i.e., molecules that do not utilize the GR for their
FIGURE 1 | Strategies to improve glucocorticoid therapy. (A) Cellular
effects of glucocorticoids (GC). GCs bind to glucocorticoid receptor (GR) and
activate intracellular signaling pathways. Previously, it was believed that
transactivation predominantly accounts for the adverse metabolic effects,
whereas transrepression/cis-repression mainly mediates anti-inflammatory
functions of GCs. (B) The strategy to develop “selective glucocorticoid
receptor modulators (SGRM)” based on the paradigm that metabolic effects
but not immune-suppressive effects depended on transactivation. (C) The
anti-inflammatory effects of GILZ are independent of GR function and may
conceivably avoid metabolic effects entirely.
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actions on inflammation. Accumulating evidence indicates that
one of the GC-induced proteins, GILZ, represents the basis for
such an approach (Figure 1C). GILZ has been detected and
functionally characterized in a wide range of immune cells,
including T lymphocytes, B lymphocytes, dendritic cells (DCs),
monocyte/macrophages, mast cells and endothelial cells (ECs)
(D’Adamio et al., 1997; Glynne et al., 2000; Berrebi et al., 2003;
Cannarile et al., 2006; Cohen et al., 2006; Godot et al., 2006;
Cheng et al., 2013). Within the most of cell types investigated,
the main function of GILZ is immune suppressive. The molecular
actions of GILZ were recently reviewed by us and others (Ayroldi
and Riccardi, 2009; Beaulieu and Morand, 2011). Although GILZ
expression is up-regulated by GCs, via GC/GR binding to GREs
within the Gilz promoter (Asselin-Labat et al., 2005), divergent
effects of GILZ and GCs on mesenchymal stem cell (MSC) differ-
entiation have been reported, suggesting that GILZ lacks an ability
to induce GC-related adverse effects (Shi et al., 2000; Zhang et al.,
2008). This notion is further supported by the observation that
GC immune suppressive functions do not always require the pres-
ence of GILZ, suggesting that GILZ and GCs work in parallel and
impact on immune system through divergent signaling pathways
(Cheng et al., 2013; Ngo et al., 2013a). In the following sections
we shall review the known effects of GC and GILZ in various cells
and compartments relevant to inflammatory disease and illustrate
evidence that their effects are divergent.
COMPARISON OF THE EFFECTS OF GC AND GILZ
To better understand the similarities and differences between
GILZ and GCs, their effects on specific cell lineages and animal
models of inflammatory diseases are directly compared in the
following sections, as summarized in Tables 1, 2.
THYMOCYTES
GCs induce thymocyte apoptosis and this effect requires
GR-dependent protein synthesis (Thomas et al., 1983; Cohen and
Duke, 1984; Ashwell et al., 2000; Bruscoli et al., 2006). Although
the mechanisms remain only partially understood, mitochondrial
apoptotic signaling pathways mediated by Bcl-2 family members
play a dominant role (Sentman et al., 1991; Grillot et al., 1995).
In addition, GCs suppress NF-κB signals in thymocytes, lead-
ing to increased thymocyte cell death (Wang et al., 1999). GILZ
was initially discovered in murine thymocytes as its expression is
exquisitely sensitive to GCs (D’Adamio et al., 1997). To elucidate
the role of GILZ in regulation of thymocyte survival, a trans-
genic (TG) mouse line, in which GILZ expression is driven by a
CD2 promoter, was generated (Delfino et al., 2004). Consistent
with GC pro-apoptotic effects, overexpression of GILZ led to
a reduction of Bcl-xL expression and accelerated anti-CD3 Ab
induced thymocyte apoptosis, which was accompanied by inhi-
bition of NF-κB p65 nuclear translocation and DNA binding
ability (Delfino et al., 2004, 2006). As a result, adult TG mice
show a decrease in CD4 and CD8 double positive thymocytes.
Moreover, a mouse strain (GRlck−Cre), in which GR expression
is conditionally knocked out in thymocytes prior to selections,
was recently generated (Mittelstadt et al., 2012). Deletion of GR
led to an absence of GC signaling and GC-induced GILZ expres-
sion. As a result, GRlck−Cre thymoctyes are completely resistance
to GC-induced apoptosis. Thus, these studies suggest that GCs
and GILZ both play a similar pro-apoptotic role in regulation of
thymocyte apoptosis.
T LYMPHOCYTES
ACTIVATION-INDUCED APOPTOSIS
In contrast to their pro-apoptotic effects on thymocytes, GC
and GILZ effects on activated T lymphocytes are anti-apoptotic
(D’Adamio et al., 1997). GCs directly interfere with AP-1 and sup-
press activation-induced FasL expression, to inhibit T lymphocyte
apoptosis (Paliogianni et al., 1993; Yang et al., 1995). The GC dex-
amethasone (DEX) also blocks NF-κB activation through inhibit-
ing IκB degradation, to reduce anti-CD3-induced FasL expression
and T cell death (Auphan et al., 1995; Liberman et al., 2012).
Similarly, GILZ inhibits anti-CD3 Ab-induced cell apoptosis in
a T cell line via directly interfering with the AP-1 transcription
factor, leading to inhibition of FasL expression and pro-apoptotic
signaling (D’Adamio et al., 1997; Mittelstadt and Ashwell, 2001).
GILZ overexpression also protects IL-2 withdrawal-induced T
lymphocyte cell death, which is correspondingly accelerated in
GILZ-deficient cells (Asselin-Labat et al., 2004). IL-2 withdrawal
rapidly induces binding of the FOXO3 transcription factor to the
GILZ promoter, leading to increased GILZ expression (Asselin-
Labat et al., 2004, 2005). On the other hand, GILZ inhibits
FOXO3 transcriptional activity via CRM1 (a nuclear transport
receptor)-dependent nuclear exclusion of FOXO3 (Latre de Late
et al., 2010), leading to decreased expression of itself and BIM, a
pro-apoptotic member of the Bcl-2 family. These findings suggest
a bidirectional regulation between FOXO3 and GILZ proteins to
regulate cell apoptosis in T lymphocytes.
IMMUNE RESPONSE
GCs suppress Th1 development and promote Th2 differentiation
in CD4 T lymphocytes, through mediating the production of a
wide range of cytokines at the transcriptional level (Kunicka et al.,
1993; Almawi et al., 1996; Miyaura and Iwata, 2002). This notion
is supported by the observation that GCs inhibit the activation
of several important T cell pro-inflammatory transcription fac-
tors, including AP-1, NFAT and NF-κB (Tsitoura and Rothman,
2004). Upon TCR activation of murine CD4 T cells, GCs reduce
production of Th1 cytokines (e.g., IL-2) and promote the expres-
sion of Th2 cytokines (e.g., IL-4) (Daynes and Araneo, 1989). It
is now clear that GCs suppress IL-2 expression via direct inhibi-
tion of AP-1 and NF-κB DNA binding activity (Vacca et al., 1992;
Adcock et al., 1995). A similar skew toward Th2 phenotype was
observed in T lymphocytes from GILZ TG mice (Cannarile et al.,
2006). Anti-CD3/anti-CD28 antibody-induced activation of the
Th2 specific transcription factors GATA3 and STAT6 is increased
in GILZ TG T lymphocytes, whereas activity of T-bet, a Th1 tran-
scription factor, was reduced (Cannarile et al., 2006). As a result,
GILZ induces T lymphocytes to produce more Th2 cytokines
(e.g., IL-4, IL-5, and IL-10) and less Th1 cytokines (e.g., INF-γ).
The concept that GILZ suppresses Th1 responses is supported
by the observation that increased IFN-γ production is detected
in GILZ knockout (KO) T cells (Ngo et al., 2013a). Moreover,
GILZ inhibits the transcriptional activity of AP-1, NF-κB and
NFAT, transcription factors known to regulate T cell activation
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Table 1 | Comparison of GILZ and GC in vitro effects on specific cell lineages.
GC effects GILZ effects
Thymocytes ↑ Apoptosis via ↑ Apoptosis via
↓ Bcl-xL, NF-κB (Wang et al., 1999; Bianchini et al., 2006;
Bruscoli et al., 2006)
↓ Bcl-xL, NF-κB (Delfino et al., 2004, 2006)
T lymphocytes ↓ Apoptosis via ↓ Apoptosis via
↓ AP-1, FasL (Zacharchuk et al., 1990; Paliogianni et al., 1993;
Yang et al., 1995)
↓ AP-1, FasL, FOXO3, BIM (Mittelstadt and Ashwell,
2001; Asselin-Labat et al., 2004; Latre de Late et al., 2010)
↓ Th1 via ↓ Th1 via
↓ IL-2, IFNγ (Daynes and Araneo, 1989; Miyaura and Iwata,
2002)
↓ IL-2, IFNγ (Ayroldi et al., 2001; Mittelstadt and Ashwell,
2001; Cannarile et al., 2006; Ngo et al., 2013a)
↑ Th2 via ↑ Th2 via
↑ IL-4, IL-10 (Daynes and Araneo, 1989; Miyaura and Iwata, 2002) ↑ GATA-3, STAT6, IL-4, IL-10 (Cannarile et al., 2006)
↓ Activation via ↓ Activation via
↓ AP-1, NF-κB, No effect on ERK (Vacca et al., 1992; Adcock
et al., 1995; Tsitoura and Rothman, 2004)
↓ AP-1, NF-κB, NFAT, ↓ ERK (Ayroldi et al., 2001, 2002;
Cannarile et al., 2006)
No effect on Th17 (McKinley et al., 2008; Nanzer et al., 2013) ↓ Th17 via
↓ IL17A (Ngo et al., 2013a)
Dendritic cells ↓ Maturation via ↓ Maturation via
↓ CD80, CD86, IL-12 (Kitajima et al., 1996; Rea et al., 2000) ↓ CD80, CD86 (Cohen et al., 2006)
↑ Tolerance via ↑ Tolerance via
↑ IL-10, B7-H1 (Rea et al., 2000; Cohen et al., 2006) ↑ IL-10, B7-H1 (Cohen et al., 2006)
↑ DC induced Treg via ↑ DC induced Treg via
↑ FOXP3+ Treg (Hamdi et al., 2007b; Unger et al., 2009) ↑ FOXP3+ Treg (Hamdi et al., 2007b)
Endothelial cells ↓ Activation via ↓ Activation via
↓ NF-κB, p38, ↑ MKP-1 (Ray et al., 1997; Furst et al., 2007;
Cheng et al., 2013)
↓ NF-κB, p38, ERK, JNK, ↑ MKP-1 (Cheng et al., 2013)
Monocyte/Macrophages ↓ Activation via ↓ Activation via
↓ NF-κB, IL-1β, TNFα (Jeon et al., 2000; Steer et al., 2000; Joyce
et al., 2001)
↓ NF-κB, IL-1β, TNFα (Berrebi et al., 2003; Hamdi et al.,
2007a)
MSC ↑ AP, ↓ OB via ↓ AP, ↓ OB via
↑ C/EBPδ, PPARγ2 (Shi et al., 2000; Yao et al., 2008) ↓ PPARγ2 (Shi et al., 2003; Zhang et al., 2008)
The effects of GCs and GILZ on each cell lineage and related mechanisms are shown. Underlined text indicates the GILZ and GC effects are divergent. Abbreviation:
AP, adipocytes; OB, osteoblasts; MSC, mesenchymal stem cells.
and differentiation (Ayroldi et al., 2001, 2002; Mittelstadt and
Ashwell, 2001), thus mimicking GC effects. GILZ directly inter-
acts with NF-κB p65 subunit through its C-terminal domain (Di
Marco et al., 2007), and inhibits p65 nuclear translocation and
DNA binding, resulting in reduced expression of IL-2 and IL-2R
(Ayroldi et al., 2001). On the other hand, the N-terminal of GILZ
interacts with AP-1 and subsequently inhibits AP-1 DNA binding,
resulting in decreased IL-2 expression (Mittelstadt and Ashwell,
2001).
Despite many similarities, several divergent effects of GCs
and GILZ on T lymphocytes activation and differentiation have
also been reported. GC effects on Th17 phenotype are not fully
understood. For example, GCs have no effect on Th17 cytokine
production from polarized Th17 T cells in vitro (McKinley et al.,
2008). As a result, neutrophil infiltration induced by adoptive
transfer of Th17 cells cannot be attenuated by GCs in vivo.
Consequently, the increased production of IL-17A and IL-22 by
asthmatic patient peripheral blood monocytes (PBMC) is insen-
sitive to GCs in vitro (Nanzer et al., 2013). In contrast, early
evidence suggests that GILZ inhibits IL-17A production as GILZ
KO T cells produce significantly more IL-17A thanWT cells (Ngo
et al., 2013a). Moreover, GCs have no effect on phosphorylation
of ERK MAP kinase in T lymphocytes activated by anti-CD3 Ab
(Tsitoura and Rothman, 2004), whereas GILZ markedly inhibits
ERK activation (Ayroldi et al., 2002). GILZ directly interacts
with and inhibits Ras/Raf, upstream kinases in the ERK pathway
(Ayroldi et al., 2002, 2007; Soundararajan et al., 2007). Together,
these observations indicate that while GILZ mimics most GC
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Table 2 | Comparison of GILZ and GC in vivo effects on animal models of diseases.
Diseases GC effects GILZ effects Techniques
Th1 Colitis (DNBS) ↓ via ↓ via GILZ TG
↓ TNFα, IL-6 (Antonioli et al., 2007) ↓ NF-κB, TNFα, IFNγ, FasL (Cannarile
et al., 2009)
Th2 Colitis (Oxazolone) Unknown ↑ via
↑ MPO (Cannarile et al., 2009)
SCI ↓ via ↓ via
↓ ROS (Hall, 2011) ↓ NF-κB, TNFα, FasL, ↓ Bcl-2 (Esposito
et al., 2012)
EAE ↓ (Chen et al., 2006) ↓ via rGILZ
↓ NF-κB, IFNγ, IL-17, ↓ GATA-3 (Srinivasan
and Janardhanam, 2011)
Experimental arthritis ↓ CIA, AIA, K/BxN (Yang et al., 2004;
Beaulieu et al., 2010; Patel et al., 2012;
Ngo et al., 2013a)
↓ CIA via GILZ-AAV
↓ IL-1, TNFα (Beaulieu et al., 2010; Ngo
et al., 2013a)
No effect (Ngo et al., 2013a) Endogenous GILZ via KO
Endotoxemia ↓ (Yang et al., 2009) ↓ via SPRET/Ei mice
↓ IL-6 (Pinheiro et al., 2013)
No effect(Ngo et al., 2013a) Endogenous GILZ via KO
DTH ↓ (Taube and Carlsten, 2000) ↓ via Endogenous GILZ via KO
↓ IFNγ, IL-17, proliferation (Ngo et al.,
2013a)
Male infertility ↑ SSC apoptosis via ↓ SSC apoptosis via
↑ FasL (Khorsandi et al., 2008; Orazizadeh
et al., 2010)
↓ ERK, AKT, FOXO1, BIM (Bruscoli et al., 2012;
Ngo et al., 2013b)
The effects of GCs and GILZ on each disease model and related mechanisms are shown. Underlined text indicates the GILZ and GC effects are divergent. The
technique by which GILZ function was examined is also listed. MPO, myeloperoxidase; SCI, spinal cord injury; EAE, experimental autoimmune encephalomyelitis;
CIA, collagen-induced arthritis; AIA, antigen-induced arthritis; SPRET/Ei, a wild-derived inbred murine strain; SSC, spermatogonia stem cells; DTH, delayed-type
hypersensitivity.
effects on T cell activation, effects on IL-17A production and ERK
activation are divergent.
DENDRITIC CELLS
DCs play a crucial role in priming naive T lymphocytes via their
ability to recognize and present antigens to T cells (Hackstein
and Thomson, 2004). GCs and GILZ have very similar suppres-
sive effects on DC activation, and many GC effects have been
suggested to be GILZ-dependent (Cohen et al., 2006; Hamdi
et al., 2007b). To mature, immature DCs need to be activated
by pro-inflammatory stimuli (e.g., TNFα), bacterial components
(e.g., LPS) or T lymphocytes expressing CD40 ligand (CD40L)
(Hackstein and Thomson, 2004). GCs inhibit DC maturation via
suppressing expression of DC maturation markers (e.g., CD80,
CD86, CD83 and IL-12), and promoting tolerance markers (e.g.,
IL-10 and B7-H1) (Kitajima et al., 1996; Rea et al., 2000; Cohen
et al., 2006). GCs also inhibit chemokine production (e.g., CCL-
3, CCL-5 and CXCL-8) by human DCs and, therefore, impair
DC ability to activate T cells (Cohen et al., 2006). Moreover,
GC-treated DCs promote the generation of regulatory T (Treg)
cells derived from pathogen-specific human CD4 T lymphocytes
(Hamdi et al., 2007b). Hamdi et al. reported that GC treat-
ment increases DC ability to induce the CD25hiFOXP3 phenotype
among human CD4+ T cells. The function of these inducible
Tregs is confirmed by their capacity to inhibit human PBMC
proliferation (Hamdi et al., 2007b). GILZ expression is highly sen-
sitive to GC treatment in human DCs and GILZ overexpression
mimics the known GC inhibitory effects on DC maturation and
activation (Cohen et al., 2006; Hamdi et al., 2007b). Consistent
with this, deficiency of endogenous GILZ induced by silencing via
siRNA reverses these GC effects, suggesting that GILZ expression
plays a critical role in mediating GC actions in DCs (Cohen et al.,
2006).
ENDOTHELIAL CELLS
ECs play a critical role in mediating the recruitment of fast-
traveling leukocytes from the blood stream to inflamed tissues.
This occurs via upregulation of the pro-inflammatory adhesion
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molecules (E-selectin, VCAM-1 and ICAM-1), and cytokines and
chemokines such as IL-6, CXCL8 and CCL2 (Ley et al., 2007).
The expression of endothelial pro-inflammatory molecules is
predominantly controlled by NF-κB and MAP kinase signaling
pathways (Chen and Manning, 1995; Kuldo et al., 2005; Cheng
et al., 2010). GC effects on the activation of human umbilical
cord vein endothelial cells (HUVECs) require GR, as GR-deficient
HUVECs show prolonged NF-κB activation (Goodwin et al.,
2013). GCs inhibit E-selectin, IL-6, VCAM-1 and ICAM-1 expres-
sion in HUVECs via interference with NF-κB (Ray et al., 1997;
Pan et al., 2011; Goodwin et al., 2013). Additionally, GCs regu-
late endothelial activation via NF-κB-independent mechanisms
(Furst et al., 2007). In HUVEC, GCs induce the expression of
MKP-1, a MAPK inhibitory phosphatase, leading to inhibition
of p38 MAPK-dependent E-selectin expression without affect-
ing NF-κB DNA binding activity (Furst et al., 2007). Consistent
with these observations, GC-treated HUVECs have impaired abil-
ity to support leukocyte rolling and transmigration under flow
conditions (Cheng et al., 2013). GILZ is highly expressed in ECs
in synovial tissue from patients with rheumatoid arthritis (RA),
and plays an important role in regulation of endothelial adhesive
functions (Beaulieu et al., 2010; Cheng et al., 2013). Similar to
the known GC effects, GILZ expression in HUVECs inhibits their
capacity to support leukocyte rolling, adhesion and transmigra-
tion, accompanied by reduced expression of E-selecting, ICAM-1,
IL-6, CXCL8, and CCL2 (Cheng et al., 2013). Differing from
observations reported in T lymphocytes, however, in a human
microvascular endothelial cell line (HMEC), GILZ inhibits NF-κB
transcription activity via suppressing NF-κB p65 DNA bind-
ing ability, without affecting its nuclear translocation, suggesting
a novel mechanism by which GILZ regulates NF-κB signaling
in human ECs. GILZ also upregulates MKP-1 expression and,
thereby, inhibits TNFα-induced p38, ERK, and JNK MAP kinase
activation, mimicking GC effects. On the other hand, GILZ
silencing via siRNA does not alter the inhibitory effects of exoge-
nous GC on HUVEC adhesive function, suggesting redundancy
of GILZ in GC effects on ECs despite the GC-mimicking effects
of GILZ (Cheng et al., 2013). Together, these observations suggest
that GCs and GILZ both play an anti-inflammatory role in regu-
lation of human EC activation, although GILZ is not required for
GC actions.
MONOCYTES/MACROPHAGES
GCs inhibit monocyte/macrophage activation via suppressing
AP-1 and NF-κB signaling, leading to reduced expression of a
wide range of pro-inflammatory genes (Mukaida et al., 1991;
Berkman et al., 1995; Marfaing-Koka et al., 1996; Jeon et al.,
2000; Steer et al., 2000; Cao et al., 2003). GILZ is constitutively
expressed in monocytes/macrophages and its expression is also
sensitive to GC treatment (Berrebi et al., 2003; Hamdi et al.,
2007a). GILZ inhibits LPS-induced production of cytokines and
chemokines such as TNFα, RANTES, IL-6, and IL-1β by human
monocytes andmacrophages in vitro, mimicking the effects of GC
(Hamdi et al., 2007a; Wang et al., 2012). Mechanistic studies in
THP-1 cells, a human monocyte cell line, show that GILZ directly
interacts with the NF-κB p65 subunit and suppresses transcrip-
tional activity, resulting in reduced expression of macrophage
activation markers CD80, CD86, and TLR2, and chemoknies
CCL5 and CCL3 (Berrebi et al., 2003). Moreover, another GC
induced anti-inflammatory protein, AnxA1, requires GILZ to
mediate inhibitory effects of GC in murine macrophage (Yang
et al., 2009). In keeping with these findings, GILZ expression
is inhibited in macrophages from patients with Crohn’s disease,
tuberculosis and alcoholic hepatitis (AH), typical inflammatory
diseases associated with macrophage activation (Berrebi et al.,
2003; Hamdi et al., 2007a). This impairment of GILZ expression
has been suggested to be implicated in prolonged macrophage
responses in these patients. GILZ mRNA stability was found to
be reduced in humanmacrophages upon Toll-like receptor (TLR)
activation (Hoppstadter et al., 2012), suggesting a mechanism for
permissive reductions in GILZ expression during inflammation.
LPS triggers TLR signaling and caused GILZ mRNA degrada-
tion in a tristetraprolin (TTP) and MyD88 dependent manner
(Hoppstadter et al., 2012). Together, these observations support
the notion that GILZ and GCs have similar inhibitory effects on
monocyte/macrophages activation via interference with NF-κB
signaling.
MESENCHYMAL STEM CELLS (MSCs)/OSTEOBLASTS
One of the main functions of multipotent MSCs is to differ-
entiate into important cell lineages, including adipocytes and
osteoblasts (Pittenger et al., 1999). The differentiation of MSCs
into adipocytes and osteoblasts is reciprocally modulated, mainly
via regulation of the activity of peroxisome proliferator-activated
receptor gamma (PPARγ2), a master transcription factor that
promotes adipogenic differentiation (Tontonoz et al., 1994;
Weinstein et al., 1998; Ahdjoudj et al., 2001; Akune et al., 2004).
GCs induce MSC differentiation toward adipocytes and suppress
osteogenic differentiation, via promoting CCAAT/enhancer-
binding protein δ (C/EBPδ) expression and its binding to the
C/EBP binding site within the PPARγ2 promoter, resulting in
increased PPARγ2 mRNA expression and transcriptional activ-
ity (Shi et al., 2000; Yao et al., 2008). This GC inhibitory effect
on osteoblast formation accounts in part for the rapid bone loss
observed in patients during GC treatment. Despite the fact that
GCs rapidly induces GILZ expression in MSCs, GILZ exerts a
completely opposite effect in the regulation of MSC differentia-
tion (Eddleston et al., 2007). GILZ expression in MSCs increases
osteogenic differentiation, and inhibits adipocyte formation (Shi
et al., 2003; Zhang et al., 2008). GILZ was reported in these stud-
ies to bind to the C/EBP site in competition with C/EBPδ, leading
to a decreased PPARγ2 expression. Together, these observations
suggest that GC and GILZ play opposite roles in regulation of
adipocyte and osteoblast formation.
ANIMAL MODELS OF INFLAMMATORY DISEASES
To better understand the role of GILZ in the regulation of inflam-
mation, GILZ effects on animal models of inflammatory diseases
have been studied. Consistent with GILZ effects on Th1/Th2 bal-
ance in vitro, the GILZ TG mice showed increased sensitivity to
bleomycin-induced neutrophil infiltration and edema, a typical
Th2 dependent model of inflammation (Cannarile et al., 2006).
Similarly, GILZ TG mice were more susceptible to oxazolone
induced Th2 colitis (Cannarile et al., 2009), consistent with the
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pro-Th2 and anti-Th1 effects of GILZ discussed above. On the
other hand, a beneficial effect of GILZ has been described in
several animal models of Th1-related inflammatory diseases. T
cell infiltration is reduced in GILZ TG mice during dinitroben-
zene sulfonic acid (DNBS)-induced colitis, accompanied by a
decrease in tissue damage, epithelial cell apoptosis, cytokine pro-
duction, as well as NF-κB activation (Cannarile et al., 2009).
Using the same GILZ TG mice, similar protective effects of GILZ
were also detected in a spinal cord injury (SCI) model, mainly
due to the GILZ inhibition of T cell activation and recruitment
(Esposito et al., 2012). Consistently, an ability of GILZ to suppress
inflammation was demonstrated in a rat model of experimen-
tal autoimmune encephalomyelitis (EAE) using an amphipathic
chariot peptide (Pep-1) for systemic administration of GILZ pro-
teins or peptides (Srinivasan and Janardhanam, 2011). Recently,
the role of GILZ in the murine collagen-induced arthritis (CIA)
model of RA was investigated, via local induction of GILZ expres-
sion in response to local injection of GILZ-adeno-associated virus
(GILZ-AAV) into the joints (Ngo et al., 2013a). GILZ expres-
sion inhibited disease development in the CIA model, mimicking
the effects of therapeutic dosing with the GC dexamethasone.
Consistent with this observation, GILZ depletion by systemic
administration of GILZ siRNA was previously found to increase
disease severity in CIA (Beaulieu et al., 2010). Moreover, the
anti-inflammatory function of GILZ has been demonstrated in
a wild-derived inbred SPRET/Ei mouse strain (Pinheiro et al.,
2013). These mice are resistant to LPS-induced endotoxemia, as
a result of increased GILZ expression due to genetic variations
(Pinheiro et al., 2013). LPS-induced IL-6 and IL-12 production
were also reduced in SPRET/Ei macrophages, and silencing GILZ
by siRNA, in contrast, completely abolished this effect (Pinheiro
et al., 2013). These studies provide direct evidence that GILZ is
a key mediator of inflammatory responses in both innate and
adaptive immune systems.
To further study biological functions of endogenous GILZ,
GILZ knockout (KO)mouse strains were recently generated inde-
pendently by four laboratories (Bruscoli et al., 2012; Romero
et al., 2012; Suarez et al., 2012; Ngo et al., 2013a). Surprisingly,
male KO animals are infertile and lack the ability to produce
sperm. Further research demonstrated that GILZ plays critical
role in regulation of spermatogonia stem cell (SSC) survival and
differentiation, likely via mediating ERK, AKT, and FOXO1 activ-
ity (Bruscoli et al., 2012; Ngo et al., 2013b). On the other hand,
no major alteration in immune responses was detected in GILZ
KO mice, despite a moderate increase in T cell proliferation and
DTH response (Ngo et al., 2013a). Surprisingly, given the effects
of GILZ therapy, GILZ deficiency failed to alter disease pheno-
types in antigen-induced arthritis (AIA), K/BxN serum-transfer
arthritis, CIA, and LPS-induced cytokinemia (Ngo et al., 2013a).
GILZ deficiency also had no effect on GC sensitivity in these
models (Ngo et al., 2013a). Consistent with this, bone marrow
macrophages of GILZ KO mice showed neither impaired inflam-
matory response to LPS, nor reduced level of sensitivity to GCs,
suggesting that GILZ is redundant for GC immune suppressive
functions in these phenomena (Suarez et al., 2012). This result is
in line with the findings described in ECs, in which GC actions
were not GILZ dependent despite inhibitory actions of GILZ
in these cells (Cheng et al., 2013). In contrast, GC effects on
DCs were abrogated on GILZ silencing, suggesting variation in
GILZ and GC impacts in different cell types. Further research is
required to elucidate the divergent molecular pathways involved
in GILZ and GC actions in these cells.
CONCLUSIONS
The studies reviewed here suggest that GILZ and GCs share many
anti-inflammatory effects on immune cells. However, differences
between GILZ and GC impacts on immune cell function and ani-
mal models of disease are evident, indicating that themechanisms
involved in the actions of GILZ and GC in specific cell types may
be different. Moreover, the requirement for GILZ in GCs actions
varies between different cell types, suggesting that GILZ media-
tion of GCs functions is cell-type-specific. The opposite effects of
GILZ and GCs on MSC differentiation raise the possibility that
development of a GILZ based gene therapy to treat inflammatory
disease could result in effects opposite to those of GC in terms
of adiposity and osteoporosis. Further investigation is required to
determine whether GILZ induces GC-related adverse metabolic
effects. If confirmed, this will support the hypothesis that GILZ
therapeutic effects mimic those of GCs but lack GC-likemetabolic
effects. As a result, GILZ-based gene therapy has great potential in
the therapy of human diseases.
KEY CONCEPTS
1. GILZ inhibits inflammatory responses in a number of impor-
tant immune cell lineages in vitro;
2. GILZ reduces disease severity in animal models of inflamma-
tory diseases in vivo, mimicking glucocorticoid effects;
3. GILZ exerts inhibitory effects on immune system independent
of glucocorticoid receptor and, thus, avoids glucocorticoid-
induced adverse metabolic effects;
4. Further investigation is required to confirm the lack of ability
of GILZ to induce GC-related side effects;
5. GILZ-based gene therapy has great potential in development
of new treatment strategies for human diseases.
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